A5103139778- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Bone health and treatments
- T-cell and Retrovirus Studies
- Neutropenia and Cancer Infections
- Ubiquitin and proteasome pathways
- Fungal Infections and Studies
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Cancer Mechanisms and Therapy
McGill University Health Centre
2025
St. Mary's Medical Center
2025
Alberta Health Services
2025
Sheba Medical Center
2025
Tel Aviv University
2025
Tel Aviv Sourasky Medical Center
2025
Catholic University of Korea
2015-2024
Seoul St. Mary's Hospital
2015-2024
Merck & Co., Inc., Rahway, NJ, USA (United States)
2019
Catholic Medical Center
2006
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus alone the primary analysis of CASTOR, phase 3 study relapsed and/or refractory multiple myeloma. A post hoc based on treatment history longer follow up is presented. After 19.4 (range: 0-27.7) months median up, daratumumab plus prolonged progression-free survival (median: 16.7 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39;...
Abstract Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of (MM). Recently, MM was redefined to include biomarkers predicting a high risk progression from SMM, thus necessitating redefinition SMM and its stratification. We assembled large cohort patients meeting the revised IMWG criteria develop new stratification system. included 1996 patients, using stepwise selection multivariable analysis, we identified three independent factors at 2 years: serum M-protein >2 g/dL...
Talquetamab (anti-G protein-coupled receptor family C group 5 member D) and teclistamab (anti-B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 have been approved for the treatment of triple-class-exposed relapsed or refractory multiple myeloma. We conducted a phase 1b-2 study talquetamab plus in patients with In 1, we investigated five dose levels dose-escalation study. at 0.8 mg per kilogram body weight 3.0 every other week was selected as...
BackgroundIn the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed.Patients MethodsEligible patients had received ≥ 1 line treatment were administered bortezomib (1.3 mg/m2) (20 mg) for 8 cycles with without daratumumab (16 mg/kg) until disease progression.ResultsOf 498 intent-to-treat (ITT) population...
The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including bortezomib and lenalidomide or thalidomide. Patients were randomly assigned (2:1) to receive 5 mg/m2 on D1 D15 40 mg D1, D8, D15, D22 (arm A, n = 171) B, 84) q4wk. primary endpoint was progression-free survival (PFS). Median PFS without disease progression (PD)...
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus (Vd) alone and exhibited tolerability in relapsed or refractory MM (RRMM). Methods This subgroup analysis evaluated D-Vd Vd CASTOR based on risk, determined using fluorescence situ hybridization and/or karyotype testing performed locally. High-risk had t(4;14), t(14;16), del17p...
Previously, the authors demonstrated positive impact of imatinib on outcome allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). Here, analyzed for risk factors that affect outcome, and they focused particularly prognostic relevance minimal residual disease level at each treatment stage.Fifty-two patients newly diagnosed Ph-positive ALL who completed following therapy were enrolled this study. For monitoring, 548...
Abstract: The proteasome inhibitor, bortezomib, has anti‐myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor‐ κ B (NF B)‐mediated pro‐inflammatory cytokines. We report a patient with who developed cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. LV exhibited marked increase serum levels IL‐6, TNF‐ α , and C‐reactive protein (CRP). administration may enhance release cytokines, which might play...
Neutrophils play an important role in immunological function. Neutropenic patients are vulnerable to infection, and except fever is present, inflammatory reactions scarce many cases. Additionally, because infections can worsen rapidly, early evaluation treatments especially febrile neutropenic patients. In cases which neutropenia anticipated due anticancer chemotherapy, antibiotic prophylaxis be used, based on the risk of infection. Antifungal may also considered if long-term or mucosal...
The recovery of myeloid-derived suppressor cells (MDSCs) and its relevance in clinical acute graft-versus-host disease (GVHD) post-hematopoietic stem cell transplantation (HSCT) infections remain to be fully characterized. We examined the expansion circulating monocytic (M-) MDSCs granulocytic (G-) at time engraftment 130 patients undergoing allogeneic HSCT (allo-HSCT). Compared with G-MDSC group, high M-MDSC group had a higher infection rate within 100 days, along worse 1-year cumulative...
Abstract REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson’s Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to disorders in individuals RBD. In turn, identifying which RBD have the highest likelihood having abnormal DAT would be useful. The objective this analysis was examine if there are basic clinical predictors Participants referred for inclusion cohort Parkinson Progression Markers...
Daratumumab, a human IgG monoclonal antibody targeting CD38, has demonstrated activity as monotherapy and in combination with standard-of-care regimens multiple myeloma. Population pharmacokinetic analyses were conducted to determine the pharmacokinetics of intravenous daratumumab therapy versus monotherapy, evaluate effect patient- disease-related covariates on drug disposition, examine relationships between exposure efficacy/safety outcomes. Four clinical studies lenalidomide/dexamethasone...
Cells of innate immunity normally recover in the first weeks to months after allogenenic hematopoietic stem cell transplantation (allo-HSCT). Their relevance terms graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect is largely unknown. The predictive role early recovery immune cells on acute GVHD GVL allo-HSCT was investigated patients with leukemia who achieved complete remission.Peripheral blood samples were taken at median 14 days (range, 12∼29 days) allo-HSCT. A...
The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via web-based data bank system.We retrospectively analyzed registered from 3,209 since 1999.The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients < or =40 years demonstrated longer OS than >65 age (median 71.13 vs. 36.73 months, p 0.001). who received novel agents at any time during their treatments showed did not 42.23 55.50 Response...
Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety clinical-grade mesenchymal cells (MSCs) has been validated, but mixed results have obtained due to heterogeneity the MSCs. In this phase I study, bone marrow-derived homogeneous clonal MSCs (cMSCs) isolated by a new subfractionation culturing method was evaluated. cMSCs were produced in GMP facility and intravenously administered patients who had...
Primary plasma cell leukemia (pPCL) is a rare and aggressive neoplasm, with rapidly progressing clinical course. We evaluated the treatment status survival outcomes of 69 Korean patients pPCL. Of them, 59 were treated; 15 (25.4%) treated initially novel agent-based regimens upfront autologous stem transplantation (ASCT), 7 (11.9%) conventional chemotherapy ASCT, 21 (35.6%) only, 16 (27.1%) alone. Overall response rates after initial therapy significantly higher in compared those...
The neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic marker in solid and hematological cancers. While the derived NLR (dNLR) was shown to be non-inferior large cohorts of patients with different cancer types, it has not been validated as a for multiple myeloma (MM) date.Between May 22, 2011 29, 2014, 176 MM from 38 centers who were ineligible autologous stem cell transplantation analyzed. dNLR calculated using complete blood count differential data. optimal cut-off value...
Efficacy and safety of bone cement augmentations for spinal pathologic fractures related to multiple myeloma, usefulness radionuclide studies surgical decision were retrospectively evaluated. Forty eight vertebrae from 27 patients augmentation procedures 48 29 conservative treatment enrolled. Clinical results using visual analogue scale (VAS) Oswestry disability index (ODI), radiologic assessed. For clinical decisions on fracture, scan or single photon emission computed tomography was done...